The malaria testing and treatment landscape in mainland Tanzania, 2016

Abstract

BackgroundUnderstanding the key characteristics of malaria testing and treatment is essential to the control of a disease that continues to pose a major risk of morbidity and mortality in mainland Tanzania, with evidence of a resurgence of the disease in recent years. The introduction of artemisinin combination therapy (ACT) as the first-line treatment for malaria, alongside policies to promote rational case management following testing, highlights the need for evidence of anti-malarial and testing markets in the country. The results of the most recent mainland Tanzania ACTwatch outlet survey are presented here, including data on the availability, market share and price of anti-malarials and malaria diagnosis in 2016.MethodsA nationally-representative malaria outlet survey was conducted between 18th May and 2nd July, 2016. A census of public and private outlets with potential to distribute malaria testing and/or treatment was conducted among a representative sample of administrative units. An audit was completed for all anti-malarials, malaria rapid (RDT) diagnostic tests and microscopy.ResultsA total of 5867 outlets were included in the nationally representative survey, across both public and private sectors. In the public sector, availability of malaria testing was 92.3% and quality-assured (QA) ACT was 89.1% among all screened outlets. Sulfadoxine–pyrimethamine (SP) was stocked by 51.8% of the public sector and injectable artesunate was found in 71.4% of all screened public health facilities. Among anti-malarial private-sector stockists, availability of testing was 15.7, and 65.1% had QA ACT available. The public sector accounted for 83.4% of the total market share for malaria diagnostics. The private sector accounted for 63.9% of the total anti-malarial market, and anti-malarials were most commonly distributed through accredited drug dispensing outlets (ADDOs) (39.0%), duka la dawa baridi (DLDBs) (13.3%) and pharmacies (6.7%). QA ACT comprised 33.1% of the national market share (12.2% public sector and 20.9% private sector). SP accounted for 53.3% of the total market for anti-malarials across both private and public sectors (31.3 and 22.0% of the total market, respectively). The median price per adult equivalent treatment dose (AETD) of QA ACT in the private sector was $1.40, almost 1.5 times more expensive than the median price per AETD of SP ($1.05). In the private sector, 79.3% of providers perceived ACT to be the most effective treatment for uncomplicated malaria for adults and 88.4% perceived this for children.ConclusionsWhile public sector preparedness for appropriate malaria testing and case management is showing encouraging signs, QA ACT availability and market share in the private sector continues to be sub-optimal for most outlet types. Furthermore, it is concerning that SP continues to predominate in the anti-malarial market. The reasons for this remain unclear, but are likely to be in part related to price, availability and provider knowledge or preferences. Continued efforts to implement governme...

The malaria testing and treatment landscape in Kenya: results from a nationally representative survey among the public and private sector in 2016

“…One option may be to permit the licensing of unregistered pharmacies through accreditation programmes, or through partnerships with the public sector, as a means to increase access to appropriate malaria case management services. Evidence from other countries has demonstrated that the registration, training and supervision of the private sector, can lend to improvements in malaria commodity ACT availability, distribution and provider performance [ 20 – 23 ].…”

Appropriateness of malaria diagnosis and treatment for fever episodes according to patient history and anti-malarial blood measurement: a cross-sectional survey from Tanzania

“…Malaria RDTs have also been deployed to reach half of the population so far, and health workers have been trained in using them [ 4 , 6 ]. Recent surveys have reported that availability of malaria testing was 83% in the public sector where more than 70% of the suspected cases were tested [ 4 , 7 ]. This was not the case in the private sector where there was only 16% of testing available [ 7 ].…”

“…Recent surveys have reported that availability of malaria testing was 83% in the public sector where more than 70% of the suspected cases were tested [ 4 , 7 ]. This was not the case in the private sector where there was only 16% of testing available [ 7 ]. Diagnosis availability and compliance to diagnosis results are major factors to reach rational use of treatments.…”

Insecticide use pattern and phenotypic susceptibility of Anopheles gambiae sensu lato to commonly used insecticides in Lower Moshi, northern Tanzania

“…Malaria is still a major cause of mortality and morbidity in sub-Saharan Africa including Tanzania [ 7 – 9 ]. The government of Tanzania has extensively provided and is scaling up free distribution of long lasting insecticidal nets [ 10 , 11 ], free anti-malarial [ 12 ] and rapid diagnostic kits [ 13 ] in all health facilities across the country as a strategy for strengthening malaria control. Vector control constitute a major component of the global strategy for malaria control [ 14 , 15 ].…”